RENAL CARE & DATA LINKAGE OF TASMANIAN KIDNEY DISEASE CASES
With
Professor Matthew Jose, Kidney Specialist
Head of Unit, Nephrology, Royal Hobart Hospital &
Professor of Medicine, University of Tasmania
Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | March 2026
Professor Matthew Jose is a Renal Physician & Head of the Renal Unit at the Royal Hobart Hospital, and Professor of Medicine for the University of Tasmania.
Winner of the 2021 Rural Science Award from the Australia and New Zealand Society of Nephrology, he has worked in regional, rural and remote Australian locations for nearly 20 years as a Renal Physician, including the Northern Territory.
He is currently Chairperson of the Tasmanian Statewide Kidney Clinical Network and a member of national clinical guideline groups including Therapeutic Guidelines and CARI guidelines kidney stone working group, as well as a member of the KidGEN (Kidney Genetics) national steering committee.
He has established the first regional young adult transplant clinic for young Tasmanians with a kidney transplant transferring from paediatric to adult care.
Professor Jose’s research has been funded by Australia’s NHMRC and MRFF, as well as Royal Hobart Hospital Research Foundation in Tasmania.
Source: Supplied and adapted
https://orcid.org/0000-0002-9589-0071
-
Applying artificial intelligence to medical imaging for cardiovascular disease detection
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
